✦ LIBER ✦

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes

✍ Scribed by P. Barrington; J. Y. Chien; H. D. H. Showalter; K. Schneck; S. Cui; F. Tibaldi; B. Ellis; T. A. Hardy

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effects of LY2189265, a long-acting

✍ G. E. Umpierrez; T. Blevins; J. Rosenstock; C. Cheng; J. H. Anderson; E. J. Bast 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 652 KB

Discovery and characterization of taspog

✍ J. Z. Dong; Y. Shen; J. Zhang; N. Tsomaia; D. F. Mierke; J. E. Taylor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 762 KB

Glucagon-like peptide-1 receptor agonist

✍ Y. Wang; L. Li; M. Yang; H. Liu; G. Boden; G. Yang 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 692 KB

Exenatide compared with long-acting insu

✍ M. J. Davies; R. Donnelly; A. H. Barnett; S. Jones; C. Nicolay; A. Kilcoyne 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 529 KB

Weight loss with liraglutide, a once-dai

✍ J. Jendle; M. A. Nauck; D. R. Matthews; A. Frid; K. Hermansen; M. Düring; M. Zdr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Clinical trial: the glucagon-like peptid

✍ P. M. HELLSTRÖM; J. HEIN; P. BYTZER; E. BJÖRNSSÖN; J. KRISTENSEN; H. SCHAMBYE 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB